Ropinirole -Neurodegenerative diseases drug-(Dec-2001)
Drug Name:
Ropinirole -Neurodegenerative diseases drug-(Dec-2001)
List Of Brands:
Indication Type Description:
Drug Interaction:
Reduce concomittant levodopa dose, Antiarrhythmics , CNS depressants, phenothizines, butyrophenones, Drugs affecting CYP1A2 such as ciprofloxacin, Cigerrete smoking, high dose ostrogens, HRT, alcohol, Other dopamine agonists metoclopramide, fluvoxamine, enoxacin, sulpride
Indication:
Parkinsons disease
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Ropinrole Parkinsons disease 03-12-2001
2.Ropinirole 6mg ER tablets 06-02-2010
Addl.stgth
same as approved
3.Ropinrole ER tablet 1mg 14-01-2011
Addl.stgth
same as approved
4.Ropinirole ER tablet 2/4/8mg 03-12-2009
For the treatment of signs and symptoms of idiopathic Parkinsons
disease
Adverse Reaction:
GI upset, dyspepsia, pharyngitis, Constipation, pain, Sweating, headache, Somnolence, fatigue, asthenia, Nausea, dizziness, Abnormal vision, arthalgia, Aggravated symptoms of Parkinsonism, Tremors, anxiety, nervousness,
Dry mouth, leg edema, Syncope, hypotension, bradycardia, Dyskinesia, hypokinesia, Paraesthesisia, confusion,hallucinations, Compulsive gambling, Sudden onset of sleep ( warn patients ) Pathological gambling, Increased libido
Contra-Indications:
Severe renal or hepatic impairment
Pregnancy,lactation Special precaution- Severe cardiovascular disease. Psychoses, neuroleptic induced akasthesia, Dyskinesia, sleep disorders Withdraw gradually.
Consider discontinuing if excessive day time sleepiness or if sudden onset of sleep during daiy activities occur.
Elderly may have higher risk of hallucinations Melonoma
Dosages/ Overdosage Etc:
Date of Approval 2001
Indication
Parkinsons disease
Dose - Adult- Week 1 - 0.25mg three times daily Week 2 - 0.5mg three times daily Week 3 - 0.75mg three times daily Week 4 - 1mg three times daily All with meals
If necessary continue to titrate in weekly intervals of upto 3mg daily Symptom control may be seen at 3-9mg daily, Maximum 24mg daily Restless leg syndrome- Initially 0.25mg once daily at bed time for 2 days If well tolerated increase to 0.5mg once daily for remainder of week.
Increase if required by 0.5mg per week to usual dose of 2mg daily Maximum- 4mg daily Not recommended for patients below 18 years
Interaction with Food:
To be taken with meals
Pregnancy and lactation:
Contraindicated for use during pregnancy and lactation.
Observe caution if use is required